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Abstract
INTRODUCTION: In ovarian cancer, new therapeutic strategies are needed because the vast majority of patients
develop a recurrence and resistance to platinum derivates. Attached to the AGO-OVAR2.11 study investigating
themultityrosine kinase inhibitor sunitinib in recurrent platinum refractory ovarian cancers, this translational research
project assesses the potential value of serum vascular endothelial growth factor (VEGF), soluble VEGF receptor-3
(sVEGFR-3), and angiopoietin-2 (Ang-2) levels for progression-free survival (PFS). MATERIALS AND METHODS:
Longitudinal serum samples were taken while the patient was on study drugs. Serum concentration of VEGF,
sVEGFR-3, and Ang-2 was determined by ELISA. The slope of the markers was correlated to the PFS. RESULTS:
Patients showing a decrease in VEGF concentration had a median PFS of 10.5 months [confidence interval (CI),
2.89–12.25] compared to 2.9 months (CI, 1.48–5.32) in the case of an increase (P = .17). The stratified log-rank test
showed a trend for longer PFS if a decrease of Ang-2 was observed (P = .089). Dichotomized in absolute decrease
or increase, the PFS was 8.4 months (CI, 2.89–12.26) versus 2.7 months (CI, 1.05–5.32), respectively. Patients with
a reduction of the sVEGFR-3 concentration had a median PFS of 4.76 months (CI 2.86–10.65) versus 8.61 months
(CI, 1.05–not estimable) in patients with an increase of sVEGFR-3. This observation was statistically not significant in
the log-rank test (P = .81). CONCLUSION: Ang-2 could potentially identify a patient population that might have a
better PFS when under anti-angiogenic treatment, like the tyrosine kinase inhibitor sunitinib.
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Introduction
Ovarian cancer is the second most deadly gynecological malig-
nancy with more than 22,000 new cases each year and more than
16,000 deaths per year [1] in the United States. In Germany, about
8000 new cases and more than 5500 deaths are reported each year
[2]. Most patients are diagnosed at an advanced International Federa-
tion of Gynecology and Obstetrics (FIGO) stage III/IV and only
20% of those patients have a long-term survival. Cytoreductive surgery
followed by combination chemotherapy of carboplatin and paclitaxel is
considered as standard of care [3,4]. Despite initial response rates of up
to 75%, themajority of patients experience a recurrence. Approximately
25% of patients develop platinum-resistant recurrence, defined as no
response to platinum-based treatment or, after initial response, a recur-
rence within 6 months after the last platinum treatment. In this situa-
tion, therapeutic options are limited. To improve patients’ symptoms
and quality of life and potentially progression-free survival (PFS) and
overall survival, new drugs or combinations are needed.
There is increasing interest in developing angiogenesis-suppressive
agents for ovarian cancer treatment and a growing number of anti-
angiogenesis drugs are currently being evaluated in clinical trials for
ovarian cancer. Bevacizumab, the monoclonal antibody targeting the
vascular endothelial growth factor (VEGF), has shown to increase the
PFS in recurrent platinum-sensitive ovarian cancer cases significantly
[5]. In addition, the incorporation of bevacizumab in the first-line
treatment of advanced ovarian cancer showed positive effects prolong-
ing PFS [6,7] and maybe even overall survival in high-risk patients.
Moreover, in women with platinum-resistant ovarian cancer, targeting
VEGF by bevacizumab combined with standard-of-care chemotherapy
improves the PFS compared to chemotherapy alone [8].
The AGO-OVAR2.11 study is a randomized phase II trial to evaluate
the objective response rate to sunitinib in recurrent platinum-resistant
ovarian cancer (EudraCT No. 2007-003089-16; ClinicalTrials.gov
Identifier: NCT 00543049). A selection design was applied to compare
two schedules of sunitinib: arm 1—50 mg sunitinib daily orally for
28 days followed by 14 days off drug and arm 2—37.5 mg sunitinib
daily continuously. The results have been published recently [9]. The
conclusion was that sunitinib shows activity in platinum-resistant ovarian
cancer and that the noncontinuous schedule seems to be more effective.
The orally available multityrosine kinase inhibitor sunitinib
(SU11248) shows anti-angiogenic activity and is approved for treating
advanced stage or recurrent renal cell carcinoma [10] as well as imatinib-
resistant gastrointestinal stromal tumors [11]. In a platinum-resistant
ovarian cancer in vivo model, sunitinib shows a significant reduction
in tumor progression [12]. Sunitinib interacts among other tyrosine
kinases with the platelet derived growth factor (PDGF) receptor and
the VEGFR, which are both expressed in ovarian cancer [13–16].
One major problem is to identify the right drug for the appropriate
patients. Another unanswered question is how to monitor the biologic
effect of these new drugs. The classic way to assess efficacy is to monitor
tumor regression by radiographic imaging. However, especially for new
types of drugs, such as anti-angiogenic drugs, it seems to be important to
establish and validate molecular, cellular, or functional surrogate markers
to monitor the activity and efficacy of anti-angiogenic compounds [17].
Angiopoietin-2 (Ang-2) is upregulated by tumor-derived VEGF in
ovarian cancer, destabilizes the host vascular structure [18], and is already
described in ovarian cancer. Soluble VEGF receptor-3 (sVEGFR-3)
overexpression was found in high-risk ovarian cancer patients predict-
ing poor outcome [19]. Patients with metastatic colorectal cancer
showed a reduction in the sVEGFR-3 concentrations under sunitinib
therapy [20]. In this translational project of the AGO-OVAR2.11
study, we determined the differential levels of VEGF, sVEGFR-3,
and Ang-2 in sera of study participants longitudinally. VEGF has
been studied quite extensively in patients treated with bevacizumab
in various types of cancer [21,22] but failed to be of predictive value
for response to this specific drug. Serum levels of VEGF, sVEGFR-3,
and Ang-2 in recurrent ovarian cancer patients before and during the
course of the targeted therapy were determined.
Materials and Methods
The AGO-OVAR2.11 trial was a multicenter, two-schedule and dose
level, randomized (1:1), open label phase II study in patients with
ovarian cancer resistant or refractory to platinum-based chemotherapy.
Women who were 18 years or older and suitable for study participa-
tion according to the inclusion and exclusion criteria were enrolled
after giving their signed and dated informed consent. The study pro-
tocol and informed consent form were reviewed and approved by an
Independent Ethics Committee at each study center. The study was
conducted by the Arbeitsgemeinschaft Gynäkologische Onkologie
(AGO) Study Group in accordance with the Declaration of Helsinki
and Good Clinical Practice guidelines. The study was designed in
accordance with the European Medicines Agency recommendations
for clinical studies in cancer patients [23] (EudraCT No. 2007-
003089-16. ClinicalTrials.gov Identifier: NCT 00543049).
Seventy-three patients were randomized (1:1 ratio) to receive either
orally 50 mg sunitinib per os (p.o.) once daily for 4 weeks of every
6-week cycle [= noncontinuous group = arm 1 (n = 36)] or 37.5 mg
sunitinib p.o. once daily continuously on a 6-week cycle [= continuous
group = arm 2 (n = 37)]. The evaluation of response was based on the
RECIST 1.0 criteria [24] in patients withmeasurable lesions. Fifty-eight
of 73 (79.5%) patients had a measurable disease. In patients without
measurable lesions, response rate was evaluated on the basis of the tumor
marker CA125 serum concentration profiles according to the recom-
mendations by the Gynecologic Cancer InterGroup (GCIG) [25,26];
serum collection was performed on each study visit. The objective re-
sponse rate and the GCIG response shared the pattern. For the transla-
tional project, each patient signed an independent inform consent.
From 43 patients, serum samples were collected, and in 29 cases,
at least two serum samples were obtained in intervals as stated in the
study protocol; first interval was 28 days, thereafter 21 days. Baseline
characteristics are summarized in Table 1.
Table 1. Baseline Characteristics of Patients.
Entire Study Population (n = 73) TR Population (n = 29)
Mean age (years) 58.6 55.4
PS ECOG 0/1 (n, %) 72 (98.6) 29 (100)
FIGO (n, %)
I–IIA 4 (5.5) 0
IIB–III 55 (75.3) 20 (69)
IV 14 (19.2) 9 (31)
Histology (n, %)
Serous 57 (78.1) 24 (82.8)
Endometrioid 5 (6.9) 2 (6.9)
Mucinous 3 (4.1) 0
Other 8 (10.9) 3 (10.3)
Postoperative tumor burden (n, %)
0 cm 25 (34.3) 12 (41.4)
<1 cm 25 (34.3) 12 (41.4)
>1 cm 17 (23.3) 5 (17.2)
PS ECOG indicates Performance Status by the Eastern Cooperative Oncology Group.
306 Predictive Markers in Recurrent Ovarian Cancer Bauerschlag et al. Translational Oncology Vol. 6, No. 3, 2013
Serum samples were collected prospectively; the scientists were
blinded to the outcome of the individual patient. Serum samples were
stored at −20°C until ELISA procedures were conducted in duplicates.
Protein concentrations of VEGF (Quantikine; Human VEGF
Immunoassay DVE00; R&D Systems Europe,Wiesbaden-Nordenstadt,
Germany), sVEGFR-3 (Human VEGFR3 DY349; R&D Systems
Europe), and Ang-2 (Quantikine; Human Angiopoioetin-2 Immuno-
assay DANG20; R&D Systems Europe) were measured using ELISA
according to the manufacturer’s protocol. In brief, for each ELISA, a
standard curve was generated and each sample was measured in dupli-
cates after 10-fold dilution. One hundred microliters of assay diluents
and 100 μl of diluted serum were added to each ELISA well and incu-
bated for 2 hours. After washing, 200 μl of VEGF/sVERGr-3/Ang-2
conjugate was added to the well, respectively, followed by a 2-hour in-
cubation. After repeated washing steps, 200 μl of substrate solution
was added and incubated for 25 minutes. Fifty microliters of stop solu-
tion was given into each well. Optical density was determined within
30 minutes using a microplate reader set to 450 nm with wavelength
correction at 540 nm.
Statistical analyses were done using SAS version 9.2.
Results
From the 73 participants, 43 individual patients gave their informed
consent to collect serum samples. At least two samples were available
for 29 patients, with a median age of 55.4 years (27–70 years). All
patients had histologic grade 2 or 3 tumors and were FIGO stage
IIIB to IV at initial diagnosis. With respect to the postoperative
tumor burden at initial surgery, 44.4% had no macroscopic tumor
and 55.6% had postoperative tumor residuals. Thirteen (44.8%) pa-
tients were randomized to the noncontinuous group, and 16 (55.2%)
were treated continuously with sunitinib.
The first value of the investigated serum markers VEGF,
sVEGFR-3, and Ang-2 served as a baseline parameter when the serum
concentration was correlated to the patients’ outcome. Using the base-
line marker separately as a continuous covariate (Cox regression),
no prognostic prediction in terms of PFS was found (Table 2).
For the most targeted therapies, no biomarker predicting the likely
response to the drug is available. To evaluate the predictive potential
of VEGF, sVEGFR-3, and Ang-2 as biomarkers during the course of
therapy, we looked at the continuous differences between the base-
line value and last available value of each patient in a Cox regression
model. Again, no significant results were observed (Table 3).
There were also no significant differences (P > .05) found after
splitting the cohorts according to the treatment arm.
Another aspect was if an absolute increase or decrease between the
first and last available values might be helpful in identifying potential
prognostic makers for PFS. For that purpose, the population of
patients joining the biomarker program was divided into two groups:
In the case of VEGF, an increase was observed in 11 cases (37.9%),
and 18 patients (62.1%) showed a reduced serum concentration
of VEGF.
Patients showing a decrease in VEGF concentration receiving
sunitinib had a median PFS of 10.5 months [confidence interval (CI),
2.89–12.25] compared to 2.9 months (CI, 1.48–5.32) in case of an
increase. In this post hoc analysis, the univariate log-rank test showed
no significance [P = .17; hazard ratio (HR), 4.37; CI, 0.44–43.1].
Ang-2 might serve as a surrogate marker to predict PFS in recur-
rent platinum-resistant ovarian cancer, since sunitinib itself is not tar-
geting this specific protein but has influences on the neoangiogenic
potency that in part is reflected by Ang-2 levels.
In the investigated cohort, 21 patients showed a lower level during
the course of therapy and 8 had higher levels of Ang-2 measured in
the serum.
Dichotomized in absolute decrease or increase, the PFS was
8.4 months (CI, 2.89–12.26) versus 2.7 months (CI, 1.05–5.32),
respectively. The stratified log-rank test showed a trend for longer
PFS if a decrease of Ang-2 was observed (P = .089; HR, 1.29; CI,
0.01–not estimable).
The sVEGFR-3 was recently described as a potential predictive
marker; therefore, we measured the serum levels in the study popula-
tion. sVEGFR-3 was found to be decreased in 86% of patients (n = 25)
and only 14% (n = 4) showed an increase. Patients with a reduction
of the sVEGFR-3 concentration had a median PFS of 4.76 months
(CI, 2.86–10.65) versus 8.61 months (CI, 1.05–not estimable) in pa-
tients with an increase of sVEGFR-3. This observation was statistically
not significant in the log-rank test (P > .8; HR, 0.71; CI, 0.04–11.8;
Table 4).
Since two dosing schedules—noncontinuous and continuous dosing—
were used in this clinical trial, we analyzed the subgroup of patients
taking part in translational project with respect to the potential influ-
ence of this actuality on the biomarker performance. No significant dif-
ferences using the univariate chi-squared test were observed (P = .68).
Discussion
Tumor cells are capable of producing angiogenic factors to pro-
mote neoangiogenesis and to avoid tumor hypoxia. Angiogenesis is
driven mainly by VEGF secreted among others by tumor cells and
Table 2. Results of the Cox Regression Model Evaluating the Baseline Values of Biomarkers (n = 29).
Standard Error Pr > ChiSq Hazard Ratio 95% Confidence Limits
VEGF <0.001 0.2112 1.001 1.000 1.002
Ang-2 <0.001 0.8130 1.000 1.000 1.001
sVEGFR-3 <0.001 0.3889 1.000 1.000 1.000
Table 3. Results of the Cox Regression Model Evaluating the Difference between Baseline and
Last Available Value of Biomarkers (n = 29).
Standard Error Pr > ChiSq Hazard Ratio 95% Confidence Limits
Diff_VEGF 0.003 0.4357 0.998 0.991 1.004
Diff_Ang-2 <0.001 0.1094 1.001 1.000 1.003
Diff_sVEGFR-3 <0.001 0.2960 1.000 0.999 1.000
Table 4. Median PFS in Patients with an Increase or Decrease in VEGF, Ang-2, or sVEGFR-3
(n = 29).
Median PFS (Months) P Value HR
Increase (n) Decrease (n)
VEGF 2.9 (11) 10.5 (18) .17 4.37
Ang-2 2.7 (8) 8.4 (21) .089 1.29
sVEGFR-3 4.8 (4) 8.6 (25) .8 0.71
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VEGFR-positive endothelial cells. Once the tumor reaches a critical
size, it does need direct blood supply; therefore, the preexisting vascular
system needs to be remodeled. VEGF plays a major role in ovarian
cancer progression and metastases [27]. Targeting VEGF in preclinical
[28] as well as in clinical settings [29] with platinum refractory ovarian
cancer seems to be a promising option. Additionally, high expression of
VEGF correlates with poor disease-free and overall survival in early-
stage ovarian cancer [30]. Enhanced angiogenesis is indicated by high
levels of VEGF and high microvessel density and is correlated with the
presence of metastases and survival [31]. Yamamoto et al. [32] found
that VEGF contributes to tumor progression in the vast majority of
ovarian tumors. All patients in this investigation showed expression
of VEGF at baseline, but the VEGF level was not predictive in terms
of PFS. These findings are in line with previous results in patients with
recurrent ovarian cancer treated with bevacizumab [21]. The authors
also looked at VEGF in corresponding plasma and did not find a dif-
ference in PFS and overall survival for baseline values. When looking at
the course of the VEGF levels under therapy, it emerged in this study
that patients with decreasing levels had a better PFS compared to those
with an increase, 10.5 months versus 2.9 months, respectively. These
findings are contradictory to the findings by Han et al., which might
be in part explained by the different drugs used. However, the results
from serum VEGF should be interpreted with caution since at least
for bevacizumab treatment a potential interference is reported [33].
In a comprehensive analysis, Hedge et al. [22] found that the base-
line plasma VEGF-A level is of prognostic value in metastatic colo-
rectal, lung, and renal cancers with patients with high levels showing
shorter overall survival. However, this investigation could not show
a predictive value of plasma VEGF-A levels for bevacizumab-based
treatment benefit.
Next to VEGF, angiopoietins (Ang-1 and Ang-2) are heavily in-
volved in tumor neovascularization. Angiopoietins are secreted and
can be measured by ELSIA tests in body fluids, e.g., patients’ serum
and/or ascites [34]. Ang-1 guards the vascular stability and architec-
ture by promoting the adhesive interactions between endothelial cells
and surrounding cells. Ang-2—being an Ang-1 antagonist—in turn
destabilizes the host vasculature in the presence of VEGF and sup-
ports angiogenesis [35]. Ang-2 solely does promote vascular regres-
sion [36,37]. In gastric cancer patients, high Ang-2 mRNA levels
reflects advanced tumor stage and poorer prognosis [38]. A high
Ang-2/Ang-1 mRNA ratio is associated with poorer outcome in
patients with hepatocellular carcinomas [39].
Zhang et al. [18] described the Ang-2 up-regulation and host vas-
cular destabilization by tumor-derived VEGF in ovarian cancer. They
found that Ang-2 was almost exclusively expressed by endothelial cells
of blood vessels localized in the tumor stroma; only a minority of
cancer cells expressed Ang-2 themselves. Tumor cells overexpressing
VEGF are triggering tumor vasculogenesis by Ang-2. In in vitro experi-
ments, VEGF induces Ang-2 transcription through VEGFR-2 (KDR)
and can be blocked be a specific KDR inhibitor [18]. This cross talk
emphasizes Ang-2 as a very interesting molecule to investigate in anti-
angiogenic therapy, especially in conjunction with sunitinib since this
molecule interferes with the receptor KDR/VEGFR-2 that promotes
Ang-2 transcription. Ang-2 seems to be more meaningful in screening
actual vasculogenesis because it is transcripted and translated in endo-
thelial cells. By immunohistochemistry and immunofluorescence,
Zhang et al. localized Ang-2 expression to CD31-positive endothelial
cells and only to a few ovarian cancer cells itself. Measuring VEGF levels
would only provide indirect inference because it gets mostly expressed
by the tumor cell itself. A hypothesis could even be that the VEGF level
would increase short term in consequence of reduced blood supply.
Destabilization in tumors with VEGF and Ang-2 overexpression lead
to disorganized large and medium caliber blood vessels with significant
pericyte loss. No changes could be detected in capillaries since those are
without a pericyte layer [18]. In their investigation, the Ang-2 value at
baseline was not predictive for the patients’ outcome. However, in our
analysis, decreased Ang-2 levels were accompanied by a trend for longer
PFS (8.4 vs 2.7 months, P = .0896).
Clinical studies using sunitinib in patients with different types of
metastatic cancer revealed members of the soluble component of the
VEGFR family as a potential surrogate marker (reviewed in [40]). In
metastatic renal cancer, a decline of sVEGFR-3 concentration was
correlated to a better outcome [41]. In contrast—although not statis-
tically significant (P > .8)—we show that patients with an increase in
sVEGFR-3 levels had a better PFS under sunitinib therapy than those
with declining serum levels, 8.6 months versus 4.8 months, respectively.
In an ovarian cancer mouse model, adenovirus-mediated gene transfer
with sVEGFR-1, sVEGFR-2, and sVEGFR-3 in combination with
paclitaxel was more effective than, e.g., the combination of paclitaxel
and bevacizumab [42]. In general, it is important to learn more about
the function and the impact of sVEGFR-3.
With respect to clinicopathologic criteria such as histologic subtype
and residual tumor after initial surgery, no statistical analyses were done
since the sample size was already small.
In the AGO-OVAR2.11 study, the residual tumor after initial sur-
gery was not considered for statistical evaluation. Most patients (89%)
within the study had received more than one chemotherapy treatment
before the study drug. Whether the residual tumor burden is of any
impact for second-line and third-line therapies remains unknown;
furthermore, the study had no statistical power to address this issue.
Whether the histologic subtype would have had any impact on the
response rate is still unclear. In the AGO-OVAR2.11 study, the
most common histologic subtype was the serous subtype, total of 57
patients (78%). All other subtypes were less frequent; therefore, a
subgroup analysis was neither performed in the AGO-OVAR2.11
study cohort nor in the translational project cohort. Whether the re-
sidual tumor burden or the histologic subtype is of any impact for
second-line and third-line therapies remains unknown; furthermore,
the AGO-OVAR2.11 study was conducted as a phase II trial and
therefore had no statistical power to address this issue.
The presented study has limitations with respect to sample size
and the exploratory nature of the investigation. The number of pa-
tients within the study and the number of samples of the transla-
tional project are small due to multiple reasons such as advanced
tumor affection and therapy-related toxicity. This highlights the dif-
ficulties in conducting biomarker correlative studies. The transla-
tional project was started to identify potential surrogate markers to
confirm them in larger study populations. It seems to be most promis-
ing to follow-up on Ang-2, although the differences were not sig-
nificant. This marker could potentially identify a patient population
that might have a better PFS when under anti-angiogenic treatment,
like the tyrosine kinase inhibitor sunitinib. In general, it might be
more successful using multiple markers than single ones. However,
it is the challenge for the future to identify at least one specific marker
or even a marker panel that could predict response to a targeted ther-
apy such as sunitinib. However, to test for marker combinations, the
sample size in clinical trials has to be high enough to provide adequate
statistical power.
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